Peptide-based innovative drug developer Peptron is launching a clinical trial of an obesity treatment designed to reduce dosing frequency from once a week to once a month.

Peptron Gets IND Approval for Phase 1 Trial of "Once-Monthly" Obesity Treatment View original image

On November 19, Peptron announced that it had received approval from the Ministry of Food and Drug Safety for the Investigational New Drug (IND) application for PT403, a once-monthly, long-acting semaglutide obesity treatment that uses the company's SmartDepot drug-delivery platform technology, which extends the duration of a drug's effects.


Following the approval, Peptron plans to conduct a Phase 1 clinical trial of PT403 in a total of 22 healthy adults at Chungnam National University Hospital. The trial will assess the safety, tolerability, and pharmacokinetic (PK) properties of PT403 after a single subcutaneous dose.


The trial is designed as a randomized, placebo-controlled, double-blind study with an active reference group. Doses will be escalated sequentially across three cohorts. Dosing in each subsequent cohort is planned to begin after the Safety Review Committee (SRC) reviews safety and tolerability data from the previous cohort.


PT403 is a long-acting injectable being developed to extend the dosing interval for semaglutide, which is widely used globally to treat obesity and diabetes, from once a week to once a month by applying Peptron's SmartDepot technology.


Following the IND approval, the company is proceeding with the steps required to initiate the clinical trial and aims to administer the first dose to a participant in December 2026. Based on the results obtained from the trial, it plans to refine its strategy for subsequent clinical development and build clinical evidence to support global development.



A Peptron representative said, "This IND approval is significant because the once-monthly semaglutide formulation, produced at our own GMP facility using our SmartDepot technology, has entered the full-fledged clinical development stage. We will advance the PT403 clinical trial without disruption, systematically assess its safety, tolerability, and pharmacokinetic properties, and build clinical evidence to support global development."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing